Table 1.
Patient demographics and treatment characteristics.
| FDCS | HS | IDCS | |
|---|---|---|---|
| Number of patients | 31 | 15 | 7 |
| Age in years (range) | 48.7 (28.7–83) | 42.3 (1.7–76.7) | 58.8 (30.3–75.6) |
| Gender (% total) | |||
| Female | 18 (58) | 6 (40) | 1 (14) |
| Male | 13 (42) | 9 (60) | 6 (86) |
| Race | |||
| White, non-hispanic | 22 (71) | 12 (80) | 6 (86) |
| Hispanic | 4 (13) | 1 (7) | 1 (14) |
| Black | 1 (3) | 1 (7) | – |
| Asian | 3 (10) | – | – |
| Unknown/other | 1 (3) | 1 (7) | – |
| KPS (% total) | |||
| ≤80% | 10 (74) | 5 (33) | – |
| 90% | 12 (26) | 4 (27) | 2 (29) |
| Unknown | 9 (29) | 6 (40%) | 5 (71) |
| Primary site (% total) | |||
| Unknown | 1 (3) | 2 (13) | 0 (0) |
| Head and neck | 8 (26) | 3 (20) | 4 (57) |
| Thoracic/chest wall | 8 (26) | 0 (0) | 2 (29) |
| Abdomen/pelvis | 13 (42) | 4 (27) | 1 (14) |
| Extremities | 0 (0) | 5 (33) | 0 (0) |
| Paraspinal/CNS/other | 1 (3) | 0 (0) | 0 (0) |
| Stage | |||
| Localised or locally advanced | 23 (74) | 6 (40) | 6 (86) |
| Metastatic | 8 (26) | 9 (60) | 1 (14) |
| Treatment characteristics | |||
| Localised disease | n = 23 | n = 6 | n = 6 |
| Surgery alone | 12 (52) | 4 (66) | 5 (83) |
| Surgery + adjuvant or neo-adjuvant therapy | 11 (48) | 2 (34) | – |
| Radiation alone | – | – | 1 (17) |
| Margin Status after surgery | N = 23 | N = 6 | N = 6 |
| Positive | 2 (9) | – | 1 (17) |
| Negative | 19 (82) | 6 (100) | 2 (33) |
| Unknown | 2 (9) | – | 3 (50) |
| Type of adjuvant/neo-adjuvant (% of N) | N = 11 | N = 2 | N = 0 |
| Neo-adjuvant Chemotherapy | 2/11 (18) | 1 (50) | – |
| Adjuvant chemotherapy | – | 1(50) | – |
| Adjuvant radiation | 9/11 (82) | – | – |
FDCS, follicular dendritic cell sarcoma; HS, histiocytic sarcoma; IDCS, interdigitating dendritic cell sarcoma; CNS, central nervous system; KPS, Karnofsky Performance Status.